nach oben

World Journal of Urology

Erschienen in:

17.10.2016 | Topic Paper

PET imaging for lymph node dissection in prostate cancer

verfasst von: Elena Incerti, Paola Mapelli, Luigi Gianolli, Maria Picchio

Erschienen in: World Journal of Urology | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

The detection of neoplastic lymph nodal involvement in prostate cancer (PCa) patients has relevant therapeutic and prognostic significance, both in the clinical settings of primary staging and restaging. Lymph nodal dissection (LND) currently represents the gold standard for evaluating the presence of lymph nodal involvement. However, this procedure is invasive, associated with morbidity, and may fail in detecting all potential lymph nodal metastatic regions. Currently the criteria for lymph nodal detection using conventional imaging techniques mainly rely on morphological assessment with unsatisfactory diagnostic accuracy. Positron emission tomography (PET) represents a helpful imaging technique for a proper staging of lymph nodal status. The most investigated PET radiotracer is choline, although many others have been explored as guide for both primary and salvage LND, such as fluorodeoxyglucose, acetate, fluorocyclobutanecarboxylic acid and prostate-specific membrane antigen. In the present review, a comprehensive literature review addressing the role of PET for LND in PCa patients is reported, with the use of the above-mentioned radiotracers.

Sankineni S et al (2015) Lymph node staging in prostate cancer. Curr Urol Rep 16(5):30CrossRefPubMed

Pond GR et al (2014) The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 65(1):3–6CrossRefPubMed

Makarov DV et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095–1101CrossRefPubMedPubMedCentral

Briganti A et al (2012) Updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection: the essential importance of percentage of positive cores. Eur Urol 61(3):480–487CrossRefPubMed

Heidenreich A et al (2014) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent—update 2013. Eur Urol 65(1):124–137CrossRefPubMed

Briganti A et al (2009) Pelvic lymph node dissection in prostate cancer. Eur Urol 55(6):1251–1265CrossRefPubMed

Loeb S, Partin AW, Schaeffer EM (2010) Complications of pelvic lymphadenectomy: do the risks outweigh the benefits? Rev Urol 12(1):20–24PubMedPubMedCentral

Barentsz JO, Thoeny HC (2015) Prostate cancer: can imaging accurately diagnose lymph node involvement? Nat Rev Urol 12(6):313–315CrossRefPubMed

Joniau S et al (2013) Mapping of pelvic lymph node metastases in prostate cancer. Eur Urol 63(3):450–458CrossRefPubMed

10.

Jung JH et al (2012) Extended pelvic lymph node dissection including internal iliac packet should be performed during robot-assisted laparoscopic radical prostatectomy for high-risk prostate cancer. J Laparoendosc Adv Surg Tech A 22(8):785–790CrossRefPubMed

11.

Martorana G, Schiavina R, Franceschelli A (2009) Should we perform imaging-guided lymph node dissection in patients with lymphatic recurrence of prostate cancer after radical prostatectomy? Eur Urol 55(6):1302–1304CrossRefPubMed

12.

Abdollah F et al (2015) Contemporary role of salvage lymphadenectomy in patients with recurrence following radical prostatectomy. Eur Urol 67(5):839–849CrossRefPubMed

13.

Berkovic P et al (2013) Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin Genitourin Cancer 11(1):27–32CrossRefPubMed

14.

Rigatti P et al (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 60(5):935–943CrossRefPubMed

15.

Di Muzio N et al (2012) Lymph nodal metastases: diagnosis and treatment. Q J Nucl Med Mol Imaging 56(5):421–429PubMed

16.

Heidenreich A et al (2016) Role of salvage lymph node dissection in prostate cancer. Curr Opin Urol 26(6):581–589CrossRefPubMed

17.

Gakis G, Stenzl A (2015) Role of 11C-choline positron emission tomography in prostate cancer recurrence—potential for delayed cure or just resetting the clock of the disease? J Urol 193(1):12–13CrossRefPubMed

18.

Picchio M et al (2015) Imaging biomarkers in prostate cancer: role of PET/CT and MRI. Eur J Nucl Med Mol Imaging 42(4):644–655CrossRefPubMed

19.

Mapelli P, Picchio M (2015) Initial prostate cancer diagnosis and disease staging—the role of choline-PET-CT. Nat Rev Urol 12(9):510–518CrossRefPubMed

20.

Jereczek-Fossa BA et al (2008) Three-dimensional conformal or stereotactic reirradiation of recurrent, metastatic or new primary tumors. Analysis of 108 patients. Strahlenther Onkol 184(1):36–40CrossRefPubMed

21.

De Bari B et al (2014) Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. Crit Rev Oncol/Hematol 90(1):24–35CrossRef

22.

Ploussard G et al (2015) Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. J Urol 194(4):983–988CrossRefPubMed

23.

Torricelli FC et al (2015) Robotic salvage lymph node dissection after radical prostatectomy. Int Braz J Urol 41(4):819 (discussion 820) CrossRefPubMedPubMedCentral

24.

Jadvar H (2009) Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET. Nat Rev Urol 6(6):317–323CrossRefPubMedPubMedCentral

25.

Beauregard JM et al (2015) FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging 15:2CrossRefPubMedPubMedCentral

26.

Chang CH et al (2003) Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. Urol Int 70(4):311–315CrossRefPubMed

27.

Bauman G et al (2012) 18F-fluorocholine for prostate cancer imaging: a systematic review of the literature. Prostate Cancer Prostatic Dis 15(1):45–55CrossRefPubMed

28.

Schiavina R, Martorana G (2013) The promise of choline-PET/CT in the detection of recurrent prostate cancer: what are the limits of our investigation? Eur Urol 63(5):797–799CrossRefPubMed

29.

Kjolhede H et al (2014) (1)(8)F-fluorocholine PET/CT compared with extended pelvic lymph node dissection in high-risk prostate cancer. World J Urol 32(4):965–970CrossRefPubMed

30.

Poulsen MH et al (2012) [18F]fluoromethylcholine (FCH) positron emission tomography/computed tomography (PET/CT) for lymph node staging of prostate cancer: a prospective study of 210 patients. BJU Int 110(11):1666–1671CrossRefPubMed

31.

Picchio M et al (2012) [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy. Eur J Nucl Med Mol Imaging 39(1):13–26CrossRefPubMed

32.

Vag T et al (2014) Preoperative lymph node staging in patients with primary prostate cancer: comparison and correlation of quantitative imaging parameters in diffusion-weighted imaging and 11C-choline PET/CT. Eur Radiol 24(8):1821–1826CrossRefPubMed

33.

Contractor K et al (2011) Use of [11C]choline PET-CT as a noninvasive method for detecting pelvic lymph node status from prostate cancer and relationship with choline kinase expression. Clin Cancer Res 17(24):7673–7683CrossRefPubMed

34.

Budiharto T et al (2011) Prospective evaluation of 11C-choline positron emission tomography/computed tomography and diffusion-weighted magnetic resonance imaging for the nodal staging of prostate cancer with a high risk of lymph node metastases. Eur Urol 60(1):125–130CrossRefPubMed

35.

Pinaquy JB et al (2015) Comparative effectiveness of [(18)F]-fluorocholine PET-CT and pelvic MRI with diffusion-weighted imaging for staging in patients with high-risk prostate cancer. Prostate 75(3):323–331CrossRefPubMed

36.

Van den Bergh L et al (2015) Final analysis of a prospective trial on functional imaging for nodal staging in patients with prostate cancer at high risk for lymph node involvement. Urol Oncol 33(3):109.e23–31PubMed

37.

Souvatzoglou M et al (2013) Comparison of integrated whole-body [11C]choline PET/MR with PET/CT in patients with prostate cancer. Eur J Nucl Med Mol Imaging 40(10):1486–1499CrossRefPubMed

38.

Piert M et al (2016) 18F-Choline PET/MRI: the additional value of PET for MRI-guided transrectal prostate biopsies. J Nucl Med 57(7):1065–1070CrossRefPubMed

39.

Piert M et al (2016) PET/MRI and prostate cancer. Clin Transl Imaging. doi:10.1007/s40336-016-0192-9

40.

Picchio M, Ratib O (2013) PET/MRI. Clin Transl Imaging 1:3–4CrossRef

41.

Ost P et al (2015) Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: a systematic review of the literature. Eur Urol 67(5):852–863CrossRefPubMed

42.

Picchio M et al (2011) The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. Eur Urol 59(1):51–60CrossRefPubMed

43.

Rinnab L et al (2008) [11C]Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197CrossRefPubMed

44.

Tilki D et al (2013) 18F-Fluoroethylcholine PET/CT identifies lymph node metastasis in patients with prostate-specific antigen failure after radical prostatectomy but underestimates its extent. Eur Urol 63(5):792–796CrossRefPubMed

45.

Passoni NM et al (2014) Utility of [11C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: results from a pathologically validated series. Urol Oncol 32(1):38.e9–16PubMed

46.

Karnes RJ et al (2015) Salvage lymph node dissection for prostate cancer nodal recurrence detected by 11C-choline positron emission tomography/computerized tomography. J Urol 193(1):111–116CrossRefPubMed

47.

Jilg CA et al (2014) Detection of lymph node metastasis in patients with nodal prostate cancer relapse using (18)F/(11)C-choline positron emission tomography/computerized tomography. J Urol 192(1):103–110CrossRefPubMed

48.

Suardi N et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309CrossRefPubMed

49.

Zattoni F, Guttilla A, Evangelista L (2016) Can (68)GA-PSMA or radiolabeled choline PET/CT guide salvage lymph node dissection in recurrent prostate cancer? Eur J Nucl Med Mol Imaging 43(8):1407–1409CrossRefPubMed

50.

Vavere AL et al (2008) 1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. J Nucl Med 49(2):327–334CrossRefPubMed

51.

Schumacher MC et al (2015) [11C]Acetate positron emission tomography-computed tomography imaging of prostate cancer lymph-node metastases correlated with histopathological findings after extended lymphadenectomy. Scand J Urol 49(1):35–42CrossRefPubMed

52.

Daouacher G et al (2016) Laparoscopic extended pelvic lymph node (LN) dissection as validation of the performance of [C]-acetate positron emission tomography/computer tomography in the detection of LN metastasis in intermediate- and high-risk prostate cancer. BJU Int 118(1):77–83CrossRefPubMed

53.

Schiavina R et al (2014) First case of 18F-FACBC PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer and negative 11C-choline PET/CT: new imaging techniques may expand pioneering approaches. Urol Int 92(2):242–245CrossRefPubMed

54.

Maurer T et al (2016) Diagnostic efficacy of gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol 195(5):1436–1443CrossRefPubMed

55.

Herlemann A et al (2016) Ga-PSMA positron emission tomography/computed tomography provides accurate staging of lymph node regions prior to lymph node dissection in patients with prostate cancer. Eur Urol. doi:10.1016/j.eururo.2015.12.051 PubMed

56.

Budaus L et al (2016) Initial experience of (68)Ga-PSMA PET/CT imaging in high-risk prostate cancer patients prior to radical prostatectomy. Eur Urol 69(3):393–396CrossRefPubMed

57.

Evangelista L et al (2016) New clinical indications for (18)F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature. Eur Urol 70(1):161–175CrossRefPubMed

58.

Hijazi S et al (2015) Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by 68 Ga-PSMA-positron emission tomography/computerized tomography. Prostate 75(16):1934–1940CrossRefPubMed

59.

Afshar-Oromieh A et al (2014) Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 41(1):11–20CrossRefPubMed

60.

Schiavina R et al (2015) (68)Ga-PSMA-PET/CT-guided salvage retroperitoneal lymph node dissection for disease relapse after radical prostatectomy for prostate cancer. Clin Genitourin Cancer 13(6):e415–e417CrossRefPubMed

61.

Heck MM et al (2014) Prospective comparison of computed tomography, diffusion-weighted magnetic resonance imaging and [11C]choline positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer patients. Eur J Nucl Med Mol Imaging 41(4):694–701CrossRefPubMed

Titel: PET imaging for lymph node dissection in prostate cancer
verfasst von: Elena Incerti
Paola Mapelli
Luigi Gianolli
Maria Picchio
Publikationsdatum: 17.10.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 4/2017
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-016-1954-8

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Neural supply of the male urethral sphincter: comprehensive anatomical review and implications for continence recovery after radical prostatectomy

Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk

Does lymph node dissection during nephroureterectomy affect oncological outcomes in upper tract urothelial carcinoma patients without suspicious lymph node metastasis on preoperative imaging studies?

Second-line treatment for metastatic clear cell renal cell cancer: experts’ consensus algorithms